ERYTHROMYCIN AND BENZOYL PEROXIDE

Post-LOE

erythromycin and benzoyl peroxide

Bausch + Lomb

ANDATOPICALGEL

Approved

Sep 2015

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

2/8 — Basic

ERYTHROMYCIN AND BENZOYL PEROXIDE (erythromycin and benzoyl peroxide) by Bausch + Lomb is clinical pharmacology the exact mechanism by which erythromycin reduces lesions of acne vulgaris is not fully known; however, the effect appears to be due in part to the antibacterial activity of the drug. First approved in 2015.

Drug data last refreshed 18h ago

Mechanism of Action

CLINICAL PHARMACOLOGY The exact mechanism by which erythromycin reduces lesions of acne vulgaris is not fully known; however, the effect appears to be due in part to the antibacterial activity of the drug. Benzoyl peroxide has a keratolytic and desquamative effect which may also contribute to its…

Pharmacologic Class:

Macrolide

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Company

Worked on ERYTHROMYCIN AND BENZOYL PEROXIDE at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.